Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant human erythropoietin.

E H Jones1

  • 1Department of Hospital Pharmacy, Cleveland Clinic Foundation, OH 44195-5102.

American Journal of Hospital Pharmacy
|November 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pet ownership increases human risk of encountering ticks.

Zoonoses and public health·2017
Same author

THE RELATION OF GLAUCOMA TO THROMBOSIS OF RETINAL VEINS, WITH NOTES OF CASES.

British medical journal·2010
Same author

Thyroid Extract in Carcinoma.

British medical journal·2010
Same author

TRAUMATIC RUPTURE OF SPLEEN: WITH A FEW NOTES ON THE BLOOD.

British medical journal·2010
Same author

The management of tonsillectomy.

The Mississippi doctor·2010
Same author

Deaths within 90 days from starting renal replacement therapy in the ERA-EDTA Registry between 1990 and 1992.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·1999

Epoetin alfa, a recombinant human erythropoietin, effectively treats anemia in dialysis patients by raising hemoglobin and hematocrit. Healthcare professionals must manage its cost, appropriate use, and potential for formulary restriction.

Area of Science:

  • Biotechnology
  • Pharmacology

Background:

  • Anemia is common in end-stage renal disease.
  • Epoetin alfa (recombinant human erythropoietin) is a new therapeutic agent.

Purpose of the Study:

  • To describe the characteristics and uses of epoetin alfa.
  • To discuss issues associated with its clinical application and economic impact.

Main Methods:

  • Review of clinical trials and FDA-approved indications.
  • Analysis of therapeutic effects, administration routes, dosing, and adverse effects.
  • Examination of economic factors and challenges for healthcare professionals.

Main Results:

  • Epoetin alfa effectively raises hemoglobin and hematocrit, improving quality of life for dialysis patients.

Related Experiment Videos

  • Adverse effects include hypertension, iron deficiency, and thrombocytosis.
  • Potential applications extend to other anemias, such as those related to chemotherapy.

    • Conclusions:

    • Epoetin alfa offers significant therapeutic and economic impact on pharmacy practice.
    • Healthcare professionals must be aware of its cost, appropriate use, and formulary considerations.
    • Its delayed therapeutic effect makes it suitable for formulary restriction.